Cleveland Clinic Head and Neck Institute, Cleveland, Ohio 44195, USA.
Laryngoscope. 2010 Jan;120(1):44-52. doi: 10.1002/lary.20667.
OBJECTIVES/HYPOTHESIS: The increased risk of malignancy associated with post-transplant immunosuppression limits the potential of laryngeal transplantation as a reconstructive option. This risk may be mitigated by utilizing decoy nuclear factor kappa B (NF-kappaB) immature dendritic cells (iDC) to provide donor-specific tolerance. The purpose of this study was to explore whether tolerogenic properties of iDC can be applied to composite tissue transplantation.
Animal study.
Five iDC-injected mice were euthanized at 15, 30, and 60 days post-laryngeal transplant. Control groups included five transplanted mice without immunosuppression, one iDC-injected mouse euthanized prior to transplantation, one mouse without injection or transplantation, and one mouse administered mature DC to serve as an accelerated rejection control. Larynges were graded for rejection severity according to a grading scale. Draining lymph nodes and spleens were evaluated by flow cytometry to determine immunogenic activity of iDC and T cells locally and peripherally.
Each time group demonstrated moderate allograft rejection (rejection severity scores: 4.38, 5.10, 5.29). NF-kappaB iDC-treated mice had significantly less rejection at all time points compared to nonimmunosuppressed mice. Flow cytometry showed inhibition of cytotoxic T cell infiltration and expansion of regulatory T cells at the allograft site.
iDC immunosuppression maintains laryngeal allograft integrity up to 60 days post-transplantation. Regulatory T cells are enhanced at the allograft site, which serves to suppress immune cell activation and induce self-antigen tolerance. iDC injection may lessen post-transplant comorbidities by decreasing the systemic immune response and favorably affecting concurrent immunosuppressive dose sequencing for laryngeal allograft preservation.
目的/假说:移植后免疫抑制与恶性肿瘤风险增加相关,限制了喉移植作为重建选择的潜力。利用诱饵核因子 kappa B(NF-kappaB)未成熟树突状细胞(iDC)提供供体特异性耐受可能减轻这种风险。本研究旨在探讨诱导耐受性的 iDC 是否可应用于复合组织移植。
动物研究。
喉移植后 15、30 和 60 天,处死 5 只接受 iDC 注射的小鼠。对照组包括 5 只未接受免疫抑制的移植小鼠、1 只在移植前接受 iDC 注射的小鼠、1 只未注射或移植的小鼠、1 只接受成熟 DC 注射的小鼠作为加速排斥对照。根据分级标准评估移植后排斥严重程度。通过流式细胞术评估引流淋巴结和脾脏,以确定 iDC 和 T 细胞在局部和外周的免疫原性活性。
每个时间组均表现为中度同种异体移植物排斥(排斥严重程度评分:4.38、5.10、5.29)。与未接受免疫抑制的小鼠相比,NF-kappaB iDC 治疗的小鼠在所有时间点的排斥反应均显著减少。流式细胞术显示,在同种异体移植物部位抑制细胞毒性 T 细胞浸润和调节性 T 细胞扩增。
iDC 免疫抑制可维持喉同种异体移植物完整性长达移植后 60 天。在同种异体移植物部位增强了调节性 T 细胞,这有助于抑制免疫细胞激活并诱导自身抗原耐受。iDC 注射可通过减少全身免疫反应和对喉同种异体移植物保存的同时免疫抑制剂量进行有利排序,从而减少移植后并发症。